Clinical Trial on Agitation in Alzheimer's Dementia (NCT05543681)
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Who can join: Review the eligibility criteria below.
Location: ClinCloud, LLC — Maitland, Florida
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- ClinCloud, LLC — Maitland, Florida
- ClinCloud, LLC — Melbourne, Florida
- Central Miami Medical Institute — Miami, Florida
- Visionary Investigators Network — Miami, Florida
- Miami Jewish Health — Miami, Florida
- Neurostudies Inc. — Port Charlotte, Florida
- BayCare Health System Inc. — St. Petersburg, Florida
- University of South Florida Department of Psychiatry and Behavioral Neurosciences — Tampa, Florida
- Tandem Clinical Research GI, LLC — Metairie, Louisiana
- MedStar Franklin Square Medical Center Neurology — Baltimore, Maryland
- Medstar Southern Maryland Hospital Center — Clinton, Maryland
- Medstar Montgomery Medical Center — Olney, Maryland
- Tekton Research LLC — St Louis, Missouri
- Dent Neurologic Institute — Amherst, New York
- Integrative Clinical Trials, LLC — Brooklyn, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Ichor Research — Syracuse, New York
- Lynn Health Science Institute (LHSI) — Oklahoma City, Oklahoma
- Butler Hospital, Brown University — Providence, Rhode Island
- Senior Adults Specialty Research — Austin, Texas
- Baylor Scott and White Research Institute — Dallas, Texas
- Kerwin Medical Center — Dallas, Texas
- Dominion Medical Associates, Inc. — Richmond, Virginia
- Island Health Authorities — Victoria, British Columbia
- Hamilton Health Sciences , Mcmaster University — Hamilton, Ontario
📞 Contact the Study Coordinator
Phone: (301) 339-4270
Email: calma@igcpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease — Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 — St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia — Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease — Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.